About xCella
xCella is a company based in Menlo Park (United States) founded in 2016 by Bob Chen was acquired by Ligand Pharmaceuticals in September 2020.. xCella offers products and services including OmniRat, OmniMouse, OmniChicken, and Omni dAb. xCella operates in a competitive market with competitors including GSK, Avidity Biosciences, PureTech Health, Sutro Biopharma and TScan Therapeutics, among others.
- Headquarter Menlo Park, United States
- Founders Bob Chen
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Omniab, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Latest Funding Round
- Investors
-
Employee Count
Employee Count
-
Acquired by
Ligand Pharmaceuticals
(Sep 10, 2020)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of xCella
xCella offers a comprehensive portfolio of products and services, including OmniRat, OmniMouse, OmniChicken, and Omni dAb. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Transgenic rat platform for human antibody production.
Transgenic mouse system for antibody discovery.
Transgenic chicken host for single-domain antibodies.
Platform for humanized single-domain antibody development.
Funding Insights of xCella
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in xCella
xCella has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Ligand Pharmaceuticals. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Pharmaceutical drugs are manufactured and developed in the United States.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by xCella
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - xCella
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Xcella Comparisons
Competitors of xCella
xCella operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Avidity Biosciences, PureTech Health, Sutro Biopharma and TScan Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of pharmaceuticals and vaccines for various therapeutic areas
|
|
| domain | founded_year | HQ Location |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| domain | founded_year | HQ Location |
Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases.
|
|
| domain | founded_year | HQ Location |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| domain | founded_year | HQ Location |
T cell-based treatments for immunological and oncological disorders are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutic antibodies are developed for cancer, autoimmune, and serious diseases.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Xcella
Frequently Asked Questions about xCella
When was xCella founded?
xCella was founded in 2016.
Where is xCella located?
xCella is headquartered in Menlo Park, United States. It is registered at Menlo Park, California, United States.
What does xCella do?
xCella was founded in 2016 and is based in Menlo Park, United States, within the biotechnology sector. Immuno-oncology antibody therapeutics are developed through the proprietary xEmplar human antibody library and xPloration functional screening technology. A pipeline targeting difficult molecules is constructed, with emphasis placed on immunomodulatory agents such as receptor agonists, G-protein coupled receptor modulators, and enzyme inhibitors. Operations center on advancing these therapeutics for oncology applications.
Who are the top competitors of xCella?
xCella's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
What products or services does xCella offer?
xCella offers OmniRat, OmniMouse, OmniChicken, and Omni dAb.
Who are xCella's investors?
xCella has 1 investor. Key investors include Ligand Pharmaceuticals.